GSK3B and non-small cell lung carcinoma: Recent evidence has shown that inhibition of GSK3β enhances the ability of the chemopreventive drug celecoxib to downregulate anti-apoptotic protein c-FLIP [7] and sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in non-small cell lung cancer (NSCLC) [8], suggesting that disruption of GSK3β activity can serve as an optional way to block lung cancer.